NQO1 and Hyperglycemia: As a downstream effector of the Nrf2 pathway—currently being targeted in clinical trials with agents such as bardoxolone methyl—NQO1’s modulation may offer compartment-specific protection against hyperglycemia-induced injury [21–23].